Recursion Pharmaceuticals

Yahoo Finance • 4 days ago

Recursion Pharmaceuticals (RXRX) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) crossed above their 200 day moving average of $5.83, changing hands as high as $5.89 per share. Recursion Pharmaceuticals Inc shares are currently trading up... Full story

Yahoo Finance • 4 days ago

Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory

We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX. Recursion Pharmaceuticals, Inc.'s share was trading at $4.6300 a... Full story

Yahoo Finance • 13 days ago

Nvidia Has Invested in These 6 Companies. Should You Follow Suit?

Key Points The GPU leader continues to invest in AI-related companies. Its mere involvement with these businesses makes them worth a look for retail investors. 10 stocks we like better than Nvidia › You've probably heard that AI chip gia... Full story

Yahoo Finance • 13 days ago

Jim Cramer on Recursion: “I Need to See a Proof of Concept Here”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated: “I don’t know. It’s been such a dog. It’s been a dog, we had... Full story

Yahoo Finance • 17 days ago

Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce

It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX [https://www.barchart.com/stocks/quotes/RXRX/overview]), you’re greeted with a clear message: Barchart’s Technical O... Full story

Yahoo Finance • 27 days ago

Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, Needham retained its Buy rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), maintaining the pri... Full story

Yahoo Finance • last month

When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts

Key Points Nvidia's largest stock holding is CoreWeave, which has more than doubled since its March IPO. Changes in the prices of Nvidia's stock holdings have had a notable positive effect on its recent earnings. Nvidia's active investing... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares

We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to... Full story

Yahoo Finance • 2 months ago

Recursion pharma director Khan sells $202k in shares

Najat Khan, a Director and Chief R&D Commercial Officer at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 36,599 shares of Class A Common Stock on August 18, 2025. The shares were sold at a price of $5.524, for a total value of $202,172.... Full story

Yahoo Finance • 2 months ago

Nvidia quietly buys more stock in AI infrastructure favorite

Nvidia quietly buys more stock in AI infrastructure favorite originally appeared on TheStreet. Nvidia has been at the center of the artificial intelligence (AI) boom, supplying the chips that power everything from cloud data centers to ge... Full story

Yahoo Finance • 2 months ago

Recursion Pharma CEO Gibson sells shares worth $3.26 million

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a $2.48 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 617,875 shares of Class A Common Stock on August 11, 2025, for approximately $3.26 million. The... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss

Recursion Pharmaceuticals (NASDAQ:RXRX [https://www.chartmill.com/stock/quote/RXRX]) reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. The company, a clinical-stage biotech... Full story

Yahoo Finance • 2 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its second quarter... Full story

Yahoo Finance • 3 months ago

The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.

Key Points Artificial intelligence-powered drug development isn't a mere premise anymore. Recursion Pharmaceuticals has made it a reality. The next era of e-commerce favors platforms like Shopify's, which allows brands to connect with con... Full story

Yahoo Finance • 3 months ago

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Stocks Crash Hard Alongside Wall Street. Recursion Pharmaceuticals dropped its share prices by 6.45 percent on Monday to close at $4.93 apiece as investors appeared to have bo... Full story

Yahoo Finance • 3 months ago

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interes... Full story

Yahoo Finance • 3 months ago

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

Investing.com -- Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts in a sector under pre... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals stock coverage resumed at Morgan Stanley

Investing.com - Morgan Stanley has resumed coverage of Recursion Pharmaceuticals (NASDAQ:RXRX) with an Equalweight rating and a $5.00 price target. According to InvestingPro data, the stock currently trades near its Fair Value, with anal... Full story

Yahoo Finance • 3 months ago

MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the open-source release of Boltz-2, which is a bio... Full story